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Advanced COPD patients under Home 
Mechanical Ventilation and/or Long Term
Oxygen Therapy: Italian Healthcare Costs
M. Vitacca1, L. Bianchi1, A. Bazza1, E.M. Clini2
The time course of the disease completely dif-
fers in COPD and chronic respiratory failure
(CRF) patients compared with patients with can-
cer: indeed, COPD patients present progressive
limitation of functions, recurrent exacerbations
and hospitalisations [6] which, in turn, further in-
creases disability and burden of costs until death
[7]. Hospital admissions occur mostly in a period
of 3.5 years with a high percentage in the six
months preceding death [8].
Very severe COPD patients at high risk of
death needing continuity of care involve a lot of
resources and money in any country. Currently
there is no unique model to provide high-quality
standard of care in these patients [9] thus there is
no evidence either for its efficacy or costs. Despite
increasing amount of prognostic indicators which
can help identify COPD patients at high risk of
death, prognosis in these patients remains uncer-
tain and extremely variable. Literature and guide-
lines offer poor recommendations for the provision
of care in most severe patients with COPD [10].
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ABSTRACT: Advanced COPD patients under Home
Mechanical Ventilation and/or Long Term Oxygen Therapy:
Italian Healthcare Costs. M. Vitacca, L. Bianchi, A. Bazza,
E.M. Clini.
Background and Aim. Little information is available
on healthcare costs for patients with very severe chronic
obstructive pulmonary disease. The aim of the current
work was to evaluate Italian healthcare costs in these pa-
tients.
Methods. Prospective 1-year analysis was assessed
in three subgroups of patients; non-invasively ventilat-
ed (n = 30); invasively-ventilated (n = 12) and on long-
term oxygen therapy (n = 41). Acute costs for care
were a sum of fees for doctor’s consultations, admis-
sions to hospital (ward and intensive care units) and
emergency drugs. Chronic costs were the sum of costs
for pharmacotherapy and home ventilation and/or oxy-
gen care.
Results. Mean cost/day/patient was 96±112€ (range 
9-526€), with acute costs accounting for 72% and chronic
costs for 28% of the total cost burden, with no significant
differences in costs associated with the three subgroups.
Acute costs had a non-normal distribution (range 0 to 510€)
being cost for hospitalisation the highest cost burden with
more than 30% of acute care costs attributed to only a small
segment of patients. Chronic care costs were also unevenly
distributed among the various groups (ANOVA p = 0.006),
being home oxygen supply the highest cost burden.
Conclusions. The current Health Care System is in ur-
gent need for a reassessment of the high cost burden asso-
ciated with hospitalisations and home oxygen supply.
Monaldi Arch Chest Dis 2011; 75: 4, 207-214.
Introduction
Worldwide, chronic obstructive pulmonary
disease (COPD) affects 9.8% of men and 5.6% of
women [1]. In Italy, an estimated 2.6 million men
and women have COPD [2] with prevalence rates
ranging from 11% to 18% according to different
criteria used for diagnosis [1]. Prevalence of the
most severe patients using oxygen therapy or
home mechanical ventilation (HMV) has been de-
scribed as 0.4% [1] and 6.6 cases per 100.000 per-
sons, respectively. 34% of HMV users are patients
with COPD [3].
The cost for COPD is a burden for the nation-
al Health Care System (HCS) which increases di-
rectly with the severity of the disease.
Hospitalisations and pharmacotherapy are the
most frequently reported large costs [1]. Annual
costs for European patients have been reported to
be in the range of 151-3,912€ [4] Most of the se-
vere COPD patients still benefit from oxygen and
ventilator support [3, 5].
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Otherwise, the policy focus on identifying a time
point for transition to case management care has
little resonance for people with very severe COPD
[11]. Careful assessment of possible supportive
and advanced care needs should be triggered at
key disease milestones along a lifetime journey
with COPD, in particular after hospital admission
for an exacerbation [11]. The current study was
aimed at prospectively reporting a 1-year costs
analysis for Italian HCS in a subgroup of very se-




All hypoxemic (less than 60 mmHg) and hy-
percapnic (more than 45 mmHg) COPD patients
with clinical prescription for HMV [delivered ei-
ther invasively (IMV) or non-invasively (NIMV)]
and/or LTOT discharged from the Respiratory De-
partment of Fondazione Salvatore Maugeri IRCCS,
Lumezzane (Italy) in the period between May 2004
and March 2007 were considered. Very severe
COPD was defined when a patient presented at least
two of the following criteria, according to [12]:
• forced expiratory volume at first second
(FEV1) predicted <30% prd,
• oxygen dependence,
• one or more hospitalisations in the year pre-
ceding the study,
• left heart failure or other co-morbidities,
• weight loss in the last 6 months or chronic
cachexia,
• decreased functional status,
• increasing dependence during activities of dai-
ly life,
• 70 years old.
The study was conducted in accordance with
the Declaration of Helsinki. Our Ethics Committee
approved the protocol. All patients signed the in-
formed consent.
Clinical Evaluation
Anthropometric and functional data were
recorded for all patients at baseline. Pre-morbidity
Life Style (PLS) score (from 0 = employed with
maximal level of autonomy to 4 = bedridden), lung
volumes, arterial blood gases and number of self
reported co-morbidities [13] were also assessed.
Mortality rate, number of exacerbations requiring
use of antibiotics and/or oral steroids, number of
admissions to hospital, intensive care unit (ICU),
and emergency room (ER), number of urgent calls
to the general practitioner (GP) were also recorded
during the 1-year follow-up period. The long-term
care programme consisted in: discussion of prefer-
ences for life sustaining treatments, holistic care
with prescription of home devices and recondi-
tioning activity to alleviate fatigue and improve
quality of life (QoL), activation of community
health services, help for caregiver burden and 3
months outpatient visits in a dedicated office; un-
structured contacts by phone were possible when
requested by patient or caregiver.
Costs Analysis for the Health Care System
1. acute costs (AC) expressed as unitary reim-
bursement (UR) by the national Diagnosis-Re-
lated-Group per single performance related to
acute events such as urgent GP consultations
(30€), ER visits (62€), medical wards admis-
sions (4.000€), ICU admissions for MV use
>96 h and with (66.661€) or without (10.113€)
tracheostomy operation need. Final costs were
computed by multiplying the number of events
(stays or activities) for the cost per prescription
as referred above;
2. chronic costs (CC) expressed as UR for home
care computed as daily cost related to LTOT
(0,006€ per liter of oxygen), NIMV rent
(3.93€/day) and IMV rent (12.5€/day). Final
costs were computed by multiplying the num-
ber of prescriptions (litres of oxygen/day and
days of rent) for the cost per unit as referred
above.
Single drug piece cost was derived from the
current marketed costs; final costs (both for acute
exacerbations and for usual chronic therapy) were
computed by multiplying the number of inhalers
used for the unitary cost/piece. Chronic personnel
costs due to nurse home care were not computed
because only 15 out 83 (18.1%) received episodic
home interventions while none received rehabilita-
tive admissions.
Statistical Analysis
Statistical analysis was performed using pack-
age SPSS software (release 12.0. SPSS, Chicago,
Il). Descriptive data is expressed as mean, standard
deviation (SD) or standard error of mean (SEM),
range or percentages where appropriate. One-way
analysis of variance (ANOVA) for multiple com-
parisons with Bonferroni’s correction was applied
to assess group differences for all variables. The
assumption for the equality of variances for the
groups was tested by means of the Levene test for
homogeneity of variances. In cases of inequality of
the variances of dependent variable, the Welch and
Brown-Forsythe statistics were used as alterna-
tives to the F test. An unpaired two-tailed t-test
was used to assess differences in variables be-
tween NIMV and IMV patients. A p-value <0.05
was considered statistically significant.
Results
Patients’ Population
83 (51%) out of 163 discharged patients with
COPD and Chronic Respiratory Failure (CRF) met
inclusion criteria and were enrolled. The mean fol-
low-up was 10±3.4 months due to 23 patients (7, 4
and 12 for NIV, IMV and LTOT respectively) who
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died before the first year of observation. The causes
of death did not differ among groups: cardiovascular
reasons in the 52%, sepsis in 30% and end stage res-
piratory causes in the remaining 18% of the cases.
Table 1 shows the anthropometric, clinical and
functional data of the study population. All pa-
tients were in severe stages of COPD and had
global CRF and respiratory muscles impairment.
They showed severe disability as shown by the
PLS, MRC scores and number of self-reported co-
morbidities. The majority of them were on LTOT
since >4 years. Study population was divided into
3 groups according to the type of home treatments:
1) NIMV = 30 patients (36.1%),
2) IMV = 12 patients (14.5%), and
3) spontaneously breathing on LTOT = 41 pa-
tients (49.4%).
Years of LTOT, hospitalisations/year, previous
ICU admissions, age, level of FEV1 and depen-
dency were different among groups. Clinical out-
comes are detailed in table 2.
Causes for Hospital Admissions
As shown in table 1 total number of co-mor-
bidities and in particular cardiovascular ones were
not different among groups. 85% of hospital ad-
missions were due to primary respiratory causes
(relapses of COPD, pneumonia and pulmonary
embolism in 50%, 30% and 20% of the cases). The
remaining admissions were computed to cardio-
vascular reasons. No differences were found for
causes of admission among the three groups of pa-
tients.
Table 2. - Clinical Outcomes
NIMV IMV LTOT ANOVA
(n = 30) (n = 12) (n = 41) p
Mortality rate (%) 23 33 29 ns
N. of exacerbations/month (mean±sd) 0.58±0.70 0.55±0.91 0.88±1.01 ns
N. of admissions in hospital/month (mean±sd) 0.26±0.24 0.15±0.16 0.29±0.33 ns
Number of admissions in ER/month (mean±sd) 0.12±0.18 0.15±0.18 0.13±0.23 ns
N. of urgent calls/month to GP (mean±sd) 0.16±0.23 0.07±0.12 0.24±0.42 ns
ER indicates emergency room; GP, general practitioner; ICU, intensive care unit; IMV, invasive mechanical ventilation;
LTOT, long-term oxygen therapy; NIMV, non-invasive mechanical ventilation.
Table 1. - Characteristics of Patients’ Population
NIMV IMV LTOT ANOVA
p
Patient Number (%) 30 (36.1) 12 (14.5) 41 (49.4) ns
Age, y 67±10 72±6 73±8 0.027
Males, n 19 8 34 ns
Ex smokers, n 23 6 29 ns
Current smokers, n 7 0 5 ns
Patients with BMI <24 (kg/m2), n 13 10 11 ns
Hospitalizations/year, n 1.70±1.06 2.92±1.24 1.54±1.33 0.011
Previous admission in ICU, (%) 50 67 32 0.01
Patients with at least one hospitalization in the last year, n 25 17 41 ns
Symptoms, y 11±8 13±7 11±7 ns
Dyspnea MRC scale ≥2 (%) 30 33 41 ns
LTOT, y 4.7±2.92 6.9±4.2 3.5±2.9 0.011
FEV1, % prd 32±14 19±2.0 41±20 0.010
VC, % prd 44±21 32±7.0 58±21 ns
PaO2, mmHg * 52±5 51±7.0 53±5 ns
PaCO2, mmHg * 49±9 54±7.0 48±9 ns
pH * 7.37±0.02 7.35±0.01 7.38±0.02 0.046
MIP, % prd 44±14 30±10 41±19 ns
MEP, % prd 46±20 38±10 47±17 ns
Co-morbidities, n 2.17±1.12 2.40±1.08 2.25±1.59 ns
PLS 2.38±0.81 3.07±0.75 2.01±0.82 0.0001
BMI indicates body mass index; FEV1 forced expiratory volume at first second; IMV, invasive mechanical ventilation; LTOT,
long-term oxygen therapy; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; MRC, Medical Research
Council; NIMV, non invasive mechanical ventilation; PLS indicates premorbidity lifestyle score; VC, vital capacity; 
*Indicates arterial blood gases measured in room air: PaCO2, carbon dioxide arterial tension and ph; PaO2, arterial oxygen tension.
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Costs Analysis for the Health Care System
The overall mean cost/day/patient was
96±112€ (range 9-526€) consisting of 72% AC
and 28% CC of the average total cost per patient
(figure 1 left panel) and totalling up to 34,820€
per patient per year (42,340€, 23,725€ and
32,120 in NIMV, IMV and LTOT, respectively).
There was no significant difference in the total
cost among groups (117±134€, 66±39€ and
88±106€ in NIMV, IMV and LTOT, respectively)
(figure 1 right panel). However, considering only
the costs for standard ward, cutting off the ICU
costs accounting for high care expenses in a few
number of patients, the overall mean cost/day/pa-
tient decreases to 56±39€ (-42%) computing for a
cost of 20,440€ per patient per year.
Acute Costs
AC per patient weren’t statistically different in
the three groups (table 3) accounting for 75% of
total costs in NIMV and LTOT, and about 50% in
IMV (figure 1 right panel).
Average daily AC (68±109€) were non-nor-
mally distributed among patients with wide range
of expense (0-510€) (figure 2 top panel). Analysis
of frequency of AC within all population showed
that 67 out of 83 patients (80.7%) cost <100€/day
(figure 2 top panel). In particular, only five pa-
tients (6%) exceeded the 95th percentile of mean
daily cost and accounted for nearly 30% of the cu-
mulative daily AC of the whole population
(1659/5723€). These five patients had, when com-
pared to the remaining ones, a longer time of oxy-
gen use, a worse FEV1, CV, PaO2 and PaCO2. Fur-
thermore, they presented a higher healthcare cost
for repeated hospitalizations and ER admissions/y,
ICU stay and relapses at home.
A further analysis among groups also con-
firmed that daily AC in NIMV patients (figure 2
left bottom) and LTOT (figure 2 right bottom)
ranged from 0 to 600€ with few patients in both
groups, using the greatest amount of expense. Con-
versely, AC in IMV patients ranged between 0 and
116€/day (figure 2 middle bottom). Hospitalisation
(either in the ward or in ICU) represented the great-
est amount of expense, being due to at least i) one
episode during the study period (table 3) in 87%
NIMV, 58% IMV and 73% LTOT patients respec-
tively, and ii) one ICU admission in 13/63 (21%)
hospitalised patients more frequently occurring in
NIMV and LTOT (23 and 12%, respectively) than
in IMV group (8%). Seventeen ICU admissions in-
terested 12 patients. Drugs and other costs (ER ac-
cesses and GP urgent calls) were <3%.
Chronic Costs
Figure 3 shows the fre-
quency distribution of CC in
the total population and by
group. 4/83 patients (5%)
exceeded the 95th percentile
of average daily cost and ac-
counted for 13% of the cu-
mulative daily CC. CC were
unevenly distributed among
groups (p=0.006) (table 4)
being expenses in the LTOT
(figure 3 right bottom) lower
than in NIMV (p=0.038)
(table 4 and figure 3 left bot-
tom) and IMV (p=0.021)
group (table 4 and figure 3
middle bottom). As expect-
ed, IMV group used major
resources for HMV rent
Fig. 1. - Health Care System burden of acute (white) and chronic (dark) costs. Costs are expressed as
average cost/patient/day for the whole group (left part) and by three different sub-groups [NIMV, IMV
and LTOT (right part)].
IMV indicates invasive mechanical ventilation; NIMV, non-invasive mechanical ventilation; LTOT =
long-term oxygen therapy.
Table 3. - Average Acute Cost (€/patient/day) of Items by Patient Groups
(€/patient/day) NIMV IMV LTOT ANOVA
(n = 30) (n = 12) (n = 41) p
Hospital admissions 34±32 24±29 36±40 0.59
ICU admissions 52±111 7±24 29±84 0.31
Drugs (antibiotics, systemic steroids) 0.8±0.7 0.7±0.7 0.8±0.9 0.83
Others 0.5±0.5 0.3±0.4 0.5±0.7 0.78
Total AC/patient 87±131 32±40 67±104 0.33
AC indicates acute costs; ICU, intensive care unit; IMV, invasive mechanical ventilation; LTOT, long-term oxygen therapy;
NIMV, non-invasive mechanical ventilation.
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when compared to NIMV. In all groups, home
oxygen supply represented the greatest cost (70%,
47% and 77% of the total CC for NIMV, IMV and
LTOT groups, respectively) while there were no
differences among groups in the items distribution.
Discussion
Our study shows that the costs for care afford-
ed by HCS for very severe patients with COPD
and CRF are considerably high.
The expense for acute events, mainly hospital-
isations, was prevalent (72%) compared with the
home care costs. Only 5% of patients used >30%
of the cumulative daily costs for acute care. De-
spite this CC was lower in spontaneously breath-
ing patients on LTOT when compared with venti-
lated patients, oxygen supply represented the
greatest expense.
COPD has a substantial HCS burden in devel-
oped countries [14] due to direct and indirect med-
ical expenses, with palliative care being a huge
contributor [1]. Few studies quantified the real
economic burden in a group of patients with very
severe COPD who have been prescribed home
oxygen and/or HMV. In this group of patients, hos-
pitalisation occurs more frequently in the final
years of life [15]. Since the time course and prog-
nosis of COPD in this subgroup of patients are
very difficult to predict, the boundary between
standard treatment and case management care is
still undefined [11, 12].
The main finding of the current study is the re-
ported average daily cost per patient in Italy for the
COPD population, which adds up to 34,820.00€
per year. This burden is not comparable to previ-
ous data reported in other countries for severe
COPD (4,400.00±2,560.00€ mean annual cost/pa-
tient) [15-28] and in Italy (mean cost/patient/
year around 2450€) [29, 30]. This difference in
costs is most certainly related to the non homoge-
neous characteristics of our patients’ population in
comparison with previous studies [15-30] in which
younger patients (age range 58-70 years) were in-
cluded. Indeed, our patients were older (71±8
years old on average) and in a very advanced stage
of the disease on the basis of FEV1 level (30%±9)
and presence of CRF (in 100% of cases), with 51%
of them under either home IMV or NIMV.
To our knowledge, only the study by Clini et
al. [31] analysed the costs in patients with func-
tional characteristics similar to those of our popu-
lation. They estimated an average annual cost per
patient of 8,240.00€ (8,660.00€ for in LTOT+
NIMV and 7,818.00€ in LTOT group). This
amount is almost twice as high as has been report-
Fig. 2. - Analysis of frequency of acute costs for the three different sub-groups (NIMV, IMV and LTOT). A minority of patients (n = 4; 4.8%) 
exceeded the 95th percentile of mean daily cost and accounted for nearly 30% of the cumulative daily acute costs of patients’ population.
IMV indicates invasive mechanical ventilation; NIMV, non-invasive mechanical ventilation; LTOT = long-term oxygen therapy.
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ed in previous studies, and also vastly different
from the values found by us.
The current study has confirmed that hospitali-
sation is the most important cost-driver represent-
ing 72% of care burden for severe and advanced
COPD, as compared with 58% of previous reports
[17-31]. Moreover, for the first time it describes
hospital costs both in standard ward and in ICU
(31% and 39% of the total average cost/year/pa-
tient, respectively). It is surprising that no signifi-
cant difference in the AC could be detected among
the three patients’ groups despite patients having
discrete variability in CRF. This result may be ex-
plained by the fact that patients admitted to ICU
more often belonged to NIMV and LTOT groups,
thus reflecting their lower clinical stability when
compared to IMV patients: the 24-h use of MV and
consequent higher home care assistance resulted in
a better stabilization of both clinical course and
blood gases. Indeed, in advanced COPD patients
we could speculate that tracheostomy might be pre-
ferred in term of stabilisation of AC (i.e. reduction
in ICU admissions) opening ethical issues and
mandatory respect about patient’s decisions on
his/her QoL. The relatively high percentage of tra-
cheostomised COPD patients in the present study
may be surprising but reflects the Italian health
habits to not refuse admission in ICU also in pa-
tients previously treated with oxygen and NIMV.
Moreover, the variability in the AC confirms
that functional data alone is not sufficient to estab-
lish illness severity and are poor predictors of
COPD time course. Consequently, these results
cannot predict the use of resources. The higher av-
erage AC in NIMV and LTOT groups may be also
explained by the high cost of tracheostomy per-
formed in ICU according to patient’s necessity,
cost not computed in the invasive tracheostomised
patients.
Finally, our study has shown that the annual
cost/patient related to chronic home care was 5-
fold higher when compared with previous data
(9,800.00€ vs. 1,845.00€) [20-28, 30] and 2-fold
higher than data by Clini et al. [31]. The highest
CC were mainly due to the higher oxygen volume
(time and flow), use of medications and rent ex-
pense for MV. The statistically significant lower
cost between LTOT and ventilation (both IMV and
NIMV) in the chronic care costs is entirely due to
the rent of ventilator machine.
Given that our studied population is similar to
that described by Andersson et al. [8] we might
Fig. 3. - Analysis of frequency of chronic costs for the three different sub-groups (NIMV, IMV and LTOT). A minority of patients (n = 4; 4.8%)
exceeded the 95th percentile of average daily cost and accounted for 13% of the cumulative daily expenses for chronic care.
IMV indicates invasive mechanical ventilation; NIMV, non-invasive mechanical ventilation; LTOT = long-term oxygen therapy.
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speculate that our cost analysis would help the
HCS to predict budgets and costs-analysis and dis-
cussing the implications on care strategies- in this
particular subset of patients, for whom the 
1-year expected expense can be extended to the es-
timated time of survival (about 4 years).
The shortcomings of this study, which may
prevent direct comparisons with other reports and
generalisation, include the small sample size, het-
erogeneity of clinical histories of enrolled patients,
and patient cohort obtained from only one Italian
hospital. Furthermore, costs might have changed
across years while Diagnostic Related Groups re-
imbursement does not necessarily reflect real costs
of individual treatment. Also in this study, home
ventilator disposables or routine laboratory tests
costs were not considered. Future studies need to
calculate indirect cost related to patients/families.
In conclusion, since transition to case manage-
ment care often impractical in COPD, holistic ap-
proach of supportive care is necessary during the
patient’s disease course [11].
Our findings suggest that health costs in very
severe patients with COPD represent a substantial
burden for HCS.
The current study offers details about the cost
of this subset of patients and shows general calcu-
lations that could be extrapolated to more precise-
ly describe the societal impact. Future studies
should address the appropriate use and provision
of HCS resources, addressing in particular new
strategies that could reduce the oxygen-related
costs (incorrect prescription, overuse, low compli-
ance, use of cheaper modality of supply) and hos-
pital admissions (structured follow-up, tele-assis-
tance) as the greatest expenses in this population.
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